ARTICLE | Clinical News

RFVIIa: Phase II data

December 13, 2010 8:00 AM UTC

The double-blind, dose-escalation, international Phase II adept 1 trial in 50 hemophilia patients experiencing a joint bleed showed that 96% of joint bleeds were well controlled in patients receiving the 2 highest doses of NN1731 vs. a historical rate of about 90% for NovoSeven. NN1731 was safe with no antibody formation against the product observed. Patients received up to 3 doses of 5, 10, 20, 40 or 80 µg/kg NN1731 or up to 3 doses 90 µg/kg NovoSeven. Data were presented at the American Society of Hematology meeting in Orlando. ...